November 21, 2019

Dear Hypoparathyroidism Association board members and community,

On behalf of Takeda, I wanted to thank you again for the opportunity to participate in a panel discussion about the NATPARA® recall in the US during the 12th International Conference on Hypoparathyroidism in Denver. Having the opportunity to hear from impacted patients – and to address their questions directly – meant a great deal to my colleague, Tom Koutsavlis, Head of US Medical Affairs at Takeda, and me. As Tom and I said at the conference, transparency is important to all of us at Takeda and, to that end, I wanted to share some recent updates with you and the hypoparathyroidism community.

In the month that’s passed since we were together, through the Special Use Program we have continued to support patients who are at extreme risk of life-threatening complications as a result of discontinuation of NATPARA. Originally intended for an extremely limited number of patients, the Special Use Program has now enrolled almost 300 patients. The higher than anticipated number of complex cases that have qualified for the Program further reinforces the significant treatment needs of the hypoparathyroidism community.

At the same time, we have been in regular contact with the Food and Drug Administration (FDA) around the short- and longer-term supply proposals we have submitted. As part of these discussions with FDA, we are focused on answering the Agency’s questions around critical considerations related to dose accuracy, safety and supply continuity. Patient safety always has been, and continues to be, the highest priority for Takeda.

In closing, I want to reiterate that we do understand and sincerely regret the impact that the NATPARA recall is having on patients. We continue to work around the clock to find ways to bring NATPARA back to the broader hypoparathyroidism community. We will provide another update as soon as we have more information to share.

Sincerely,

Cheryl Schwartz
Head of US Hematology & Rare Business Unit

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about NATPARA?

Warning: Possible bone cancer (osteosarcoma).

- During animal drug testing, NATPARA caused some rats to develop a bone cancer called osteosarcoma. It is not known if people who take NATPARA will have a higher chance of getting
Tell your doctor right away if you have any of these signs and symptoms of high or low blood calcium levels.

Who should not use NATPARA?

- Do not use NATPARA if you are allergic to parathyroid hormone or any of the ingredients in NATPARA.

What should I tell my healthcare provider before using NATPARA?

- Before you start using NATPARA, tell your doctor about all of your medical conditions. Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of NATPARA?

- NATPARA may cause serious side effects like allergic (hypersensitivity) reaction, including anaphylaxis. Tell your healthcare provider or get emergency medical help right away if you have any of the following symptoms of an allergic reaction:
  - swelling of your face, lips, mouth, or tongue
  - breathing problems
  - fainting, dizziness, feeling lightheaded (low blood pressure)
  - fast heartbeat

  - itching
  - rash
  - hives
• **The most common side effects of NATPARA include:** tingling, tickling, or burning feeling of the skin, low or high blood calcium, headache, nausea, reduced sense of touch or sensation, diarrhea, vomiting, pain in joints, too much calcium in urine, and pain in limbs.

**These are not all the possible side effects of NATPARA. For more information, talk with your doctor.**

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit [www.fda.gov/medwatch](http://www.fda.gov/medwatch) or call 1-800-FDA-1088.

Please go to [https://www.shirecontent.com/PI/PDFs/Natpara_USA_ENG.pdf](https://www.shirecontent.com/PI/PDFs/Natpara_USA_ENG.pdf) for the Full Prescribing Information and Medication Guide.